These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22359236)

  • 1. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
    Lamond NW; Skedgel C; Rayson D; Lethbridge L; Younis T
    Breast Cancer Res Treat; 2012 Jun; 133(3):1115-23. PubMed ID: 22361999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
    Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
    PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
    Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
    Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.
    Kondo M; Hoshi SL; Ishiguro H; Toi M
    Breast Cancer Res Treat; 2012 Jun; 133(2):759-68. PubMed ID: 22315134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
    Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
    J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
    Kondo M; Hoshi SL; Yamanaka T; Ishiguro H; Toi M
    Breast Cancer Res Treat; 2011 Jun; 127(3):739-49. PubMed ID: 21082239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
    Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
    Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
    Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
    Kip M; Monteban H; Steuten L
    J Comp Eff Res; 2015 Sep; 4(5):433-45. PubMed ID: 25872415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    Hall PS; McCabe C; Stein RC; Cameron D
    J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.